Ertugliflozin Significantly Reduces Functional Mitral Regurgitation in Heart Failure patients : Study Dr Riya Dave9 May 2024 10:15 AM ISTResearchers have found that ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves left ventricular global...
SGLT2 Inhibitors vs. DPP4 Inhibitors: Study reveals new benefits of SGLT2i for prevention of hypertension Medha Baranwal24 April 2024 10:00 AM ISTJapan: A recent study published in Hypertension Research using nationwide real-world data demonstrated the potential advantage of SGLT2 inhibitors...
Among diabetes patients, SGLT2 inhibitors less likely to cause gout compared to sulfonylureas: JAMA Medha Baranwal20 April 2024 10:00 AM ISTUSA: The use of SGLT2 inhibitors versus sulfonylureas was associated with a lower risk of incident gout, heart failure (HF), and major adverse...
Bexagliflozin found as effective as dapagliflozin for glycemic control in diabetes: Study Medha Baranwal11 April 2024 9:30 AM ISTChina: A 24-week, phase 3 trial has shed light on the safety and efficacy of bexagliflozin versus dapagliflozin as an adjunct to metformin in Chinese...
SGLT2 inhibitors may protect T2D patients with AF from HF and renal complications: Study Jacinthlyn Sylvia9 April 2024 10:00 AM ISTA recent study found a significant discovery in the treatment of patients with from type 2 diabetes (T2D) with concurrent atrial fibrillation (AF)...
Role of SGLT2 inhibitors beyond diabetes care to metabolic care: Indian Perspective Medha Baranwal3 April 2024 9:00 PM ISTIndia: A recent article published in the Indian Journal of Endocrinology and Metabolism has presented an Indian perspective on the paradigm shift of...
Advancing therapy with iGlarLixi safe and effective for diabetes treatment irrespective of SGLT2 inhibitors use: Study Medha Baranwal3 April 2024 2:15 AM ISTA patient-level pooled analysis of three randomized clinical trials (RCTs) revealed improvement in glycemic status without increased risk of...
SGLT2 Inhibitors Improve Skeletal Muscle Pathology in Heart Failure, reveals study Dr Riya Dave1 April 2024 7:45 PM ISTPatients with heart failure and reduced ejection fraction (HFrEF) often experience skeletal muscle pathology, contributing to symptoms and reduced...
SGLT2 inhibitors clinically beneficial in patients with gout, suggests review Medha Baranwal29 March 2024 6:45 PM ISTUSA: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors may provide improved outcomes in treating gout and its common comorbidities, a recent...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
Canagliflozin improves diabetic kidney disease by inducing fasting-like and aestivation-like metabolic patterns: Study Medha Baranwal22 Feb 2024 6:00 AM ISTChina: Canagliflozin (CANA) regulates metabolic reprogramming in diabetic kidney disease (DKD) by inducing fasting-like and aestivation-like metabolic...
SGLT2 inhibitors preferred oral antidiabetic for individuals with both NAFLD and T2D,reveals study Dr Riya Dave15 Feb 2024 9:30 AM ISTNonalcoholic fatty liver disease (NAFLD) is prevalent among individuals with type 2 diabetes (T2D) and presents a significant health burden. While...
